Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Olfactory transduction | R-HSA-9751605 | map04740 | carbamazepine | 2554 | drug-path |
Asthma | R-HSA-444620 | map05310 | carbamazepine | 2554 | drug-path |
MAPK signaling pathway | R-HSA-9652817 | map04010 | carbamazepine | 2554 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | carbamazepine | 2554 | drug-path |
Alzheimer's disease | R-HSA-1643685 | 0 | carbamazepine | 2554 | drug-path |
Focal adhesion | R-HSA-354113 | map04510 | carbamazepine | 2554 | drug-path |
Parkinson's disease | R-HSA-1643685 | 0 | carbamazepine | 2554 | drug-path |
Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | carbamazepine | 2554 | drug-path |
Small cell lung cancer | R-HSA-5619066 | map05222 | carbamazepine | 2554 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | blebbistatin | 6473883 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | blebbistatin | 6473883 | drug-path |
Antigen processing and presentation | R-HSA-1236975 | map04612 | blebbistatin | 6473883 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | blebbistatin | 6473883 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | blebbistatin | 6473883 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | blebbistatin | 6473883 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | natamycin | 5284447 | drug-path |
Axon guidance | R-HSA-422475 | map04360 | natamycin | 5284447 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | natamycin | 5284447 | drug-path |
Shigellosis | 0 | map05131 | natamycin | 5284447 | drug-path |
Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | natamycin | 5284447 | drug-path |